NCT05476939 2026-02-05
BIOMEDE 2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
Clinical Trials
6 trialsNCT06012929 2026-01-26
A Study of ONC201 for Refractory Meningioma
University of Nebraska
Phase 2 Withdrawn
NCT05009992 2025-12-17
PNOC022
University of California, San Francisco
Phase 2 Recruiting
NCT05580562 2025-08-26
ACTION
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT04617002 2025-08-20
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Jazz Pharmaceuticals
Approved for marketing
NCT03295396 2025-07-28
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Jazz Pharmaceuticals
Phase 2 Terminated